Home Biosimilar Antibodies Immunology & Inflammation CCR Leronlimab (anti-CCR5)
For research use only. Not for use in humans.

Leronlimab (anti-CCR5)

Synonyms: PRO 140

Leronlimab (anti-CCR5) （PRO 140; Vyrologix）is a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. It is being investigated as a potential therapy in the treatment of HIV infection.

Leronlimab (anti-CCR5)

Click to purchase the isotype control of Leronlimab (anti-CCR5)

Quality Control

Batch: Purity: 99% Protein concentration: 3.19mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CCR CCR1 CCR2 CCR3 CCR4 CCR5 CCR9 CCL Others
SB-328437 0
INCB3344 7 mCCR2
RS504393 1
C-021 0
Vercirnon 0
BX471 (ZK-811752) 3
PF-4136309 1
Vicriviroc maleate 1
RS-102895 Hydrochloride 1 human α1a receptor,human α1d receptor,5-HT1a receptor
RS102895 2
TAK-779 0 CXCR3
AZD2098 2
Adaptavir (DAPTA) 3
R243 2
Perillaldehyde 1 NRF2/HO1,ROS,AhR
Cenicriviroc 9 HIV-2,HIV-1
Isuzinaxib (APX-115 free base) 2 TNFα,IL-6,NOX2
SB-297006 4
BMS-813160 2
Bindarit (AF 2838) 25
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Leronlimab (anti-CCR5) （PRO 140; Vyrologix）is a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy. It is being investigated as a potential therapy in the treatment of HIV infection.
In vitro

Leronlimab binds CCR5 in multiple breast cancer cell lines, reducing ligand-induced Ca+ 2 signaling, invasion of TNBC into Matrigel, and transwell migration, also enhances the breast cancer (BCa) cell killing of the BCa chemotherapy reagent, doxorubicin.
Cell Research

Equal numbers of cells were plated, and after 72 h of exposure to the drugs, cells were incubated with 1 mg/mL of MTT for 90 min. The reduced (insoluble and colored) formazan was dissolved in 0.04 N HCl acidified isopropanol and measured spectrophotometrically at 570 nm.
In vivo

In xenografts conducted with Nu/Nu mice, leronlimab reduces lung metastasis of the TNBC cell line, MB-MDA-231, reducing the metastatic tumor burden of established TNBC lung metastasis.
Animal Research

AnimalModels:Female NCI Athymic nu/nu nude mice injected with MB-MDA-231 cells expressing Luc2-eGFP
Dosages:2 mg/mouse
Administration:i.p.[1]

 
References

Product Details

CAS No. 674782-26-4
Molecular Weight 146.7 KD
Isotype Human IgG4
Application Leronlimab (anti-CCR5)
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20 mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06699836 ACTIVE_NOT_RECRUITING Drug: 350 mg leronlimab|Drug: 700 mg leronlimab Metastatic Colorectal Cancer (mCRC) CytoDyn, Inc. 2025-06-16 PHASE2
NCT07553338 RECRUITING Drug: Leronlimab (700mg) Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease; Alzheimer's Disease Weill Medical College of Cornell University 2026-04-30 PHASE2
NCT05730673 WITHDRAWN Drug: 700mg leronlimab weekly dose|Drug: 80mg Regorafenib at CCR5; Microsatellite Stable; Metastatic; Colorectal Cancer CytoDyn, Inc. 2022-09-20 PHASE2
NCT04901689 SUSPENDED Drug: Leronlimab|Drug: Placebo COVID-19 Pneumonia Hospital Israelita Albert Einstein 2021-10-23 PHASE3
NCT04901676 SUSPENDED Drug: Leronlimab|Drug: Placebo COVID-19 Pneumonia Hospital Israelita Albert Einstein 2021-09-09 PHASE3
NCT03838367 TERMINATED Drug: 350 mg leronlimab|Drug: 525 mg leronlimab|Drug: 700 mg Triple Negative Breast Neoplasms CytoDyn, Inc. 2019-04-22 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-05-18)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.